Neuronetics Stock Price, News & Analysis

Neuronetics (NASDAQ: STIM) reported Q3 2025 revenue of $37.3M, up 11% adjusted pro forma versus Q3 2024 and up 101% on an unadjusted basis, driven largely by the Greenbrook acquisition. U.S. Greenbrook clinic revenue was $21.8M (adjusted pro forma +25%). Gross margin declined to 45.9% from 75.6% year-over-year, reflecting clinic mix. Net loss was $(9.4)M (EPS $(0.13)). Cash totaled $34.5M at quarter end and cash used in operations improved to $0.8M in Q3. The company secured an additional $10M debt tranche from Perceptive and raised $7.8M net via an ATM offering. CEO Keith J. Sullivan plans to retire effective June 30, 2026 with a successor search underway.

Full-year 2025 revenue guidance was updated to $147M–$150M and Q4 revenue is expected at $40M–$43M.

Neuronetics (NASDAQ: STIM) granted inducement restricted stock units to twelve new employees on Oct 31, 2025 under Nasdaq Listing Rule 5635(c)(4), approved by its Compensation Committee and issued under the Company’s 2020 Inducement Incentive Plan.

The awards vest subject to continued service and include individual grants of 1,500 RSUs (seven recipients), 4,500 RSUs (two recipients), 11,250 RSUs (one recipient), 7,500 RSUs (one recipient), and 600 RSUs (one recipient), totaling 38,850 RSUs across twelve employees with multi‑year vesting schedules.

Neuronetics (NASDAQ: STIM) entered an exclusive three-year agreement with Elite DNA Behavioral Health to be the sole provider of transcranial magnetic stimulation (TMS) devices across Elite DNA’s 30+ locations. The collaboration also uses Neuronetics’ Greenbrook platform to deliver expanded fee-based operational and patient-support services, including PHQ-10 processing, TMS consultations, and scheduling. A pilot launched in Q4 2025 with plans to scale in 2026. The partnership is framed as a scalable, systemized model to expand NeuroStar access and streamline administrative operations for Elite DNA clinics.

Neuronetics (NASDAQ: STIM) will release its third quarter 2025 financial and operating results before market open on Tuesday, November 4, 2025.

The company will host a live conference call and webcast to review results at 8:30 a.m. Eastern Time the same day. The webcast will be available in listen-only mode at https://edge.media-server.com/mmc/p/yxrs8osc. Telephone participation requires registration; joining 10 minutes early is recommended.

Neuronetics (NASDAQ: STIM), maker of NeuroStar® Advanced Therapy, announced that New York State Medicaid will expand coverage for Transcranial Magnetic Stimulation (TMS) therapy to treat major depressive disorder (MDD). The coverage will be effective October 1, 2025 for fee-for-service members and November 1, 2025 for Managed Care Plans.

This expansion will provide TMS access to over 5 million New York Medicaid members, including nearly 1 million fee-for-service beneficiaries and 4.4 million individuals with Managed Care Organizations. NeuroStar's non-drug, non-invasive treatment has demonstrated up to 83% response rate and 62% remission rate for MDD patients.

Neuronetics (NASDAQ: STIM), a commercial stage medical technology company, has announced inducement awards for six new employees under NASDAQ Listing Rule 5635(c)(4). The awards consist of restricted stock units (RSUs) ranging from 1,200 to 18,750 units per employee, with specific vesting schedules over 3-4 years.

The company specializes in neuroscience treatments, notably the NeuroStar Advanced Therapy System, which has delivered over 7.4 million treatments for major depressive disorder (MDD). Through Greenbrook TMS centers, Neuronetics has provided more than 1.8 million treatments to over 55,000 patients struggling with depression.

Neuronetics (NASDAQ: STIM) reported strong Q2 2025 financial results with total revenue of $38.1 million, representing an 18% adjusted pro forma growth year-over-year. The company achieved record Greenbrook clinic revenue of $23.0 million and reduced cash burn to $3.5 million.

Key highlights include shipping 41 NeuroStar systems at the highest ASP in 5 years (over $85,000), treating over 209,000 global patients, and securing an additional $10 million in funding from Perceptive Advisors. The company reported a net loss of $(0.15) per share and appointed Steven Pfanstiel as new CFO.

For full-year 2025, Neuronetics maintains revenue guidance of $149-155 million, expects gross margin of 48-50%, and projects positive cash flow from operations in Q4 2025.

Neuronetics (NASDAQ: STIM), a medical technology and healthcare company focused on neurohealth therapies, has announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. Keith Sullivan, President and CEO, will deliver a presentation on Tuesday, August 12, 2025, at 1:30 PM ET.

The presentation will be accessible to registered attendees and presenting companies through the conference portal for 14 days following the event.

Neuronetics (NASDAQ: STIM) announced significant findings published in JAACAP Open regarding the effectiveness of NeuroStar TMS therapy in treating adolescent and young adult depression. The study, based on the world's largest TMS outcomes dataset, analyzed 1,283 patients aged 12-21 and found that approximately 70% of patients showed clinically meaningful improvement.

Since receiving FDA clearance in March 2024 for treating adolescents aged 15-21, NeuroStar has seen a one-third increase in adolescent treatments. The research demonstrated similar efficacy to adult populations, with less than 1% reporting worsening symptoms. The study is particularly significant as only two FDA-approved medications exist for adolescent depression, both carrying major safety warnings.